Navigation Links
Pevion's Therapeutic Candida Vaccine Shows Robust Systemic and Mucosal Immunogenicity, While Epidemiological Survey Confirms Excellent Market Potential
Date:10/11/2011

ical needs based on its clinically and commercially validated virosome technology. Its proprietary clinical pipeline includes a first-in-class candidiasis vaccine. A clinical stage malaria vaccine candidate has been successfully outlicensed, and the Company's technology has been licensed for use as an HIV vaccine currently in human trials. Pevion has in-house development capability and expertise, including a state-of-the-art and industrially scalable GMP manufacturing process. Located near Bern, Pevion was established by its founding fathers, Bachem AG (SWX: BANB) and Berna Biotech (now Crucell, a Johnson & Johnson subsidiary). To date, Pevion has raised a total of CHF 45 million from its founders and investors, BZ Bank, Bachem, BB Biotech Ventures and private investors.

For more information visit http://www.pevion.com  

For further information, please contact: Julian Wagner, PhD, Business Development, Phone: +41-31-550-44-44, info@pevion.com


'/>"/>
SOURCE Pevion Biotech AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
2. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
3. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
4. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
5. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
6. ShangPharma Subsidiary and Jiangsu Hengrui Medicine Partner in Therapeutic Antibody Research and Development
7. Healthpoint Biotherapeutics to Present at UBS Global Life Sciences Conference
8. PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
9. CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics
10. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
11. FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Discovery Laboratories, Inc. (Nasdaq: DSCO ) ... $1.0M tranche under a previously awarded Phase II ... up to $3.0 million to support continued development ... potential medical countermeasure to mitigate acute and chronic/late-phase ... initial $1.0 million under this grant in October ...
(Date:7/29/2015)... , July 30, 2015 ... reports results for the second quarter of 2015. ... group,s results and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics ... Q2 results - Performance drivers ...
(Date:7/29/2015)... 29, 2015 US-Australian drug discovery company, Novogen ... it is committed to progressing its ground-breaking technology platforms ... and to ensure the Company delivers the best value ... Iain Ross , said the Company currently had an ... programs, discovery programs and academic partnerships and initiatives, and ...
(Date:7/29/2015)... July 29, 2015  HealthSouth Corporation (NYSE: ... providers of post-acute healthcare services, offering both facility-based ... of operations for the second quarter ended June 30, ... characterized by strong volume growth in both segments ... said Jay Grinney, President and Chief Executive Officer ...
Breaking Biology Technology:Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25
... PARK, Md. -- University of Maryland physicists have ... mobility, a measure of how well a material conducts ... room temperature. Graphene, a single-atom-thick sheet of graphite, is ... metals. , Their results, published online in the journal ...
... Osteotech, Inc.,(Nasdaq: OSTE ), a leader in ... announced today that the United States Patent and,Trademark ... Patent No.,5,676,146. The ,146 patent covers mixtures of ... radiopaque material, such as nondemineralized,or partially demineralized bone, ...
... research companies invested a record $58.8,billion last year ... and vaccines -- an increase of nearly $3 ... Research and Manufacturers of,America (PhRMA) and Burrill & ... 50th anniversary, which it observes today., This ...
Cached Biology Technology:UM physicists show electrons can travel over 100 times faster in graphene than in silicon 2UM physicists show electrons can travel over 100 times faster in graphene than in silicon 3U.S. Patent Office Confirms Validity of Osteotech's U.S. Patent No. 5,676,146 2R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007 2R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007 3
(Date:7/7/2015)... Calif. , July 7, 2015  Based ... market, Frost & Sullivan recognizes Credence ID, LLC ... Entrepreneurial Company of the Year Award. Credence ... to aid in its mission of offering enrollment ... populations globally. As Credence ID was formed by ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) has ... Market by Application, Technology, Function & Geography - Global ... The next generation biometrics market is expected to ... 17.9% between 2015 and 2020 Travel & ... Safran SA ( France ), NEC ...
(Date:6/30/2015)... June 30, 2015 Genisphere announced ... CEO to help further develop Genisphere,s therapeutics capabilities and ... experience, having spent much of the last 25 years ... Baxter Bioscience, and Johnson & Johnson. Tom started his ... and Biotech Corporate Finance. He graduated from Dartmouth College ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... Stromal Caveolin-1 Predicts Breast Cancer Prognosis Two ... American Journal of Pathology demonstrate the role of ... cancer progression. These articles are highlighted by an ... endocytosis and signal transduction, plays a major role in ...
... (22 May 2009)The Global Crop Diversity Trust announced today ... the millions of seed samples maintained in 1,500 crop ... critically needed to protect food production from the ravages ... wide range of innovative projects, including a search in ...
... Once placed into a patient,s body, stem cells intended ... wreaking havoc simply because they are no longer under ... has the potential to solve this problem, according to ... Medical Center published in a recent issue of the ...
Cached Biology News:Tips from the American Journal of Pathology 2Tips from the American Journal of Pathology 3Tips from the American Journal of Pathology 4Tips from the American Journal of Pathology 5Hunt for 'climate-ready' crops accelerates as organizations search seed collections worldwide 2Hunt for 'climate-ready' crops accelerates as organizations search seed collections worldwide 3Gene therapy could expand stem cells' promise 2
... enables sensitive, fast and specific detection of ... Short hybridisation time ( ... spreads Multiplex capability Available with ... Probes available with different labels. ...
... is a K-12 strain ideally suited as ... high transformation efficiency, blue/white screening capability (with ... result in high yields of excellent quality ... is potentially useful as a stringent host ...
... kit contains all the reagents required for ... c reductase activity in cell and tissue ... (ER)]. It has been tested on samples ... kidney, brain, spleen, and heart muscle from ...
... is an automated, confocal, real-time, single cell ... been integrated into a single, compact unit. ... provide high-resolution, automated confocal imaging with sophisticated ... cell-based assays. The system allows the user ...
Biology Products: